[CME/CPE Cat 3A: Gastroenterology] Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a systematic review and meta-analysis

For Healthcare Professionals Only.
Journal: BMC Gastroenterology
Validity Period (for CME): February 2026

(click to expand) Information for Doctor CME Category 3A (Self-study)

CME points will be awarded to doctors who submit claims for reading papers from Refereed Journals recommended by SMC or listed in PubMed. Papers must be published within the last 2 years. Claims from other publications, such as newsletters, magazines or non-refereed journals, will be rejected. This article serves as a concise overview of the key insights extracted from the original article. Hence, ensure to cite the actual research paper in your CME Cat. 3A claim. Link to the paper is provided in the footnotes. For more information, visit: [Criteria], [List]

(click to expand) Information for Pharmacist CPE Category 3A (Reading)

CPE points will be award to pharmacists who submit claims for reading papers from the list of journals recommended by the SPC if they wish to minimise the rejection of claims for reading non-recognised materials. This article serves as a concise overview of the key insights extracted from the original article. Hence, ensure to cite the actual research paper in your CPE Cat. 3A claim. Link to the paper is provided in the footnotes. For more information, visit: [Main], [Guide, Page 26], [List]

Background of Colorectal Cancer Treatment

  • Colorectal cancer is a prevalent malignancy worldwide, constituting a significant portion of cancer diagnoses.
    • Over 1.8 million cases diagnosed in 2018, ranking as the third most common cancer globally.
    • Approximately 25% of colon cancer cases are diagnosed as stage II in Western countries.

You must be healthcare professional to view this content.

POMConnect Banner2 Email Bottom

Copyright ยฉ 2025 DocMed Technology Pte Ltd. All rights reserved.